Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03294616
Other study ID # IRB00089514
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 6, 2017
Est. completion date November 20, 2019

Study information

Verified date November 2019
Source Johns Hopkins University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

An innovative method of needleless transcutaneous electroacupuncture (TEA) using a newly developed watch-size stimulator is proposed. Weak electrical current will be delivered via skin surface electrodes to acupuncture points related to gastrointestinal functions. The stimulator can be attached to the skin near the acupuncture points and therefore daily activity of the patient does not need to be altered. Two experiments are designed to prove the feasibility of the proposed therapy for gastric complications of Scleroderma .


Recruitment information / eligibility

Status Completed
Enrollment 23
Est. completion date November 20, 2019
Est. primary completion date June 30, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- No any systemic diseases;

- no scleroderma; no history of gastrointestinal surgery;

- no dyspeptic symptoms during the past 2 weeks;

- not taking any medications except contraceptives during the past 2 weeks;

- age 18 and older.

Exclusion Criteria:

- History of any systemic diseases or surgeries;

- allergic to adhesives; pregnancy;

- unable to sign the consent form.

Study Design


Intervention

Device:
transcutaneous electroacupuncture
Weak electrical current will be generated by the device and delivered via skin surface electrodes to acupuncture points related to gastrointestinal functions

Locations

Country Name City State
United States Johns Hopkins Bayview Medical Center Baltimore Maryland

Sponsors (1)

Lead Sponsor Collaborator
Johns Hopkins University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary effect of TEA on symptoms in Systemic Sclerosis (SSc) patients On the first visit; The validated UCLA SCTC GIT2.0 ("University of California at Los Angeles Scleroderma Clinical Trials Consortium Gastro-Intestinal Tract Instrument version 2.0") for SSc will be the primary outcome measurement; it includes 7 categories: reflux, distention and bloating, fecal soilage, diarrhea, social functioning, emotional well-being and constipation 1 day
Primary effect of TEA on symptoms in Systemic Sclerosis (SSc) patients On the second visit; The validated "University of California at Los Angeles Scleroderma Clinical Trials Consortium Gastro-Intestinal Tract Instrument version 2.0" (UCLA SCTC GIT2.0) for SSc will be the primary outcome measurement; it includes 7 categories: reflux, distention and bloating, fecal soilage, diarrhea, social functioning, emotional well-being and constipation 28 days
Primary effect of TEA on symptoms in Systemic Sclerosis (SSc) patients On the third visit; The validated UCLA SCTC GIT2.0 ("University of California at Los Angeles Scleroderma Clinical Trials Consortium Gastro-Intestinal Tract Instrument version 2.0") for SSc will be the primary outcome measurement; it includes 7 categories: reflux, distention and bloating, fecal soilage, diarrhea, social functioning, emotional well-being and constipation 42 days
Primary effect of TEA on symptoms in Systemic Sclerosis (SSc) patients The validated UCLA SCTC GIT2.0 ("University of California at Los Angeles Scleroderma Clinical Trials Consortium Gastro-Intestinal Tract Instrument version 2.0") for SSc will be the primary outcome measurement; it includes 7 categories: reflux, distention and bloating, fecal soilage, diarrhea, social functioning, emotional well-being and constipation 70 days
Primary effect of TEA on symptoms in Systemic Sclerosis (SSc) patients Scleroderma Health Assessment Questionnaire will be used to assess SSc symptoms 1 day
Primary effect of TEA on symptoms in Systemic Sclerosis (SSc) patients Scleroderma Health Assessment Questionnaire will be used to assess SSc symptoms 28 days
Primary effect of TEA on symptoms in Systemic Sclerosis (SSc) patients Scleroderma Health Assessment Questionnaire will be used to assess SSc symptoms 42 days
Primary effect of TEA on symptoms in Systemic Sclerosis (SSc) patients Scleroderma Health Assessment Questionnaire will be used to assess SSc symptoms 70 days
Primary effect of TEA on symptoms in Systemic Sclerosis (SSc) patients SF-36 questionnaire will be used to assess general quality of life 1 day
Primary effect of TEA on symptoms in Systemic Sclerosis (SSc) patients SF-36 questionnaire will be used to assess general quality of life 28 days
Primary effect of TEA on symptoms in Systemic Sclerosis (SSc) patients SF-36 questionnaire will be used to assess general quality of life 42 days
Primary effect of TEA on symptoms in Systemic Sclerosis (SSc) patients SF-36 questionnaire will be used to assess general quality of life 70 days
Primary effect of TEA on symptoms in Systemic Sclerosis (SSc) patients a validated method including 9 symptoms will be used to assess GI symptoms 1 day
Primary effect of TEA on symptoms in Systemic Sclerosis (SSc) patients a validated method including 9 symptoms will be used to assess GI symptoms 28 days
Primary effect of TEA on symptoms in Systemic Sclerosis (SSc) patients a validated method including 9 symptoms will be used to assess GI symptoms 42 days
Primary effect of TEA on symptoms in Systemic Sclerosis (SSc) patients a validated method including 9 symptoms will be used to assess GI symptoms 70 days
Secondary effects of TEA on gastric motility visit 1 in acute phase; gastric slow waves recording 1 week
Secondary effects of TEA on gastric motility visit 2 in acute phase; gastric slow waves recording 2 weeks
Secondary effects of TEA on gastric motility visit 3 in acute phase; gastric slow waves recording 3 weeks
Secondary effects of TEA on gastric motility visit 4 in acute phase; gastric slow waves recording 4 weeks
Secondary effects of TEA on autonomic function visit 1 in acute phase; heart rate variability recording 1 week
Secondary effects of TEA on autonomic function visit 2 in acute phase; heart rate variability recording 2 weeks
Secondary effects of TEA on autonomic function visit 3 in acute phase; heart rate variability recording 3 weeks
Secondary effects of TEA on autonomic function visit 4 in acute phase; heart rate variability recording 4 weeks
Secondary effects of TEA on gastric motility visit 1 in chronic phase; gastric slow waves recording 1 day
Secondary effects of TEA on gastric motility visit 2 in chronic phase; gastric slow waves recording 28 days
Secondary effects of TEA on gastric motility visit 3 in chronic phase; gastric slow waves recording 42 days
Secondary effects of TEA on gastric motility visit 4 in chronic phase; gastric slow waves recording 70 days
Secondary effects of TEA on gastric motility visit 1 in chronic phase; breath test will be used to assess gastric emptying 1 day
Secondary effects of TEA on gastric motility visit 2 in chronic phase; breath test will be used to assess gastric emptying 28 days
Secondary effects of TEA on gastric motility visit 3 in chronic phase; breath test will be used to assess gastric emptying 42 days
Secondary effects of TEA on gastric motility visit 4 in chronic phase; breath test will be used to assess gastric emptying 70 days
Secondary effects of TEA on autonomic function visit 1 in chronic phase; heart rate variability recording 1 day
Secondary effects of TEA on autonomic function visit 2 in chronic phase; heart rate variability recording 28 days
Secondary effects of TEA on autonomic function visit 3 in chronic phase; heart rate variability recording 42 days
Secondary effects of TEA on autonomic function visit 4 in chronic phase; heart rate variability recording 70 days
Secondary effects of TEA on autonomic function visit 1 in chronic phase; Composite Autonomic Symptoms Score (COMPASS) 31 survey will be used to assess autonomic function 1 day
Secondary effects of TEA on autonomic function visit 2 in chronic phase; Composite Autonomic Symptoms Score (COMPASS) 31 survey will be used to assess autonomic function 28 days
Secondary effects of TEA on autonomic function visit 3 in chronic phase; Composite Autonomic Symptoms Score (COMPASS) 31 survey will be used to assess autonomic function 42 days
Secondary effects of TEA on autonomic function visit 1 in chronic phase; Composite Autonomic Symptoms Score (COMPASS) 31 survey visit 4 in chronic phase; will be used to assess autonomic function 70 days
Secondary effects of TEA on autonomic function baseline before the study; NE (indication of sympathetic activity) will be assessed using ELISA autonomic function. 1 day
Secondary effects of TEA on autonomic function baseline before the study; NE (indication of sympathetic activity) will be assessed using ELISA autonomic function. 28 days
Secondary effects of TEA on autonomic function baseline before the study; NE (indication of sympathetic activity) will be assessed using ELISA autonomic function. 42 days
Secondary effects of TEA on autonomic function baseline before the study; NE (indication of sympathetic activity) will be assessed using ELISA autonomic function. 70 days
Secondary effects of TEA on autonomic function 30 minutes after the testing meal; NE (indication of sympathetic activity) will be assessed using ELISA autonomic function. 1 day
Secondary effects of TEA on autonomic function 30 minutes after the testing meal; NE (indication of sympathetic activity) will be assessed using ELISA autonomic function. 28 days
Secondary effects of TEA on autonomic function 30 minutes after the testing meal; NE (indication of sympathetic activity) will be assessed using ELISA autonomic function. 42 days
Secondary effects of TEA on autonomic function 30 minutes after the testing meal; NE (indication of sympathetic activity) will be assessed using ELISA autonomic function. 70 days
Secondary effects of TEA on autonomic function 60 minutes after the testing meal; NE (indication of sympathetic activity) will be assessed using ELISA autonomic function. 1 day
Secondary effects of TEA on autonomic function 60 minutes after the testing meal; NE (indication of sympathetic activity) will be assessed using ELISA autonomic function. 28 days
Secondary effects of TEA on autonomic function 60 minutes after the testing meal; NE (indication of sympathetic activity) will be assessed using ELISA autonomic function. 42 days
Secondary effects of TEA on autonomic function 60 minutes after the testing meal; NE (indication of sympathetic activity) will be assessed using ELISA autonomic function. 70 days
Secondary effects of TEA on autonomic function baseline before the study; pancreatic polypeptide (PP, indication of vagal activity) will be assessed using ELISA autonomic function. 1 day
Secondary effects of TEA on autonomic function baseline before the study; pancreatic polypeptide (PP, indication of vagal activity) will be assessed using ELISA autonomic function. 28 days
Secondary effects of TEA on autonomic function baseline before the study; pancreatic polypeptide (PP, indication of vagal activity) will be assessed using ELISA autonomic function. 42 days
Secondary effects of TEA on autonomic function baseline before the study; pancreatic polypeptide (PP, indication of vagal activity) will be assessed using ELISA autonomic function. 70 days
Secondary effects of TEA on autonomic function 30 minutes after the testing meal; pancreatic polypeptide (PP, indication of vagal activity) will be assessed using ELISA autonomic function. 1 day
Secondary effects of TEA on autonomic function 30 minutes after the testing meal; pancreatic polypeptide (PP, indication of vagal activity) will be assessed using ELISA autonomic function. 28 days
Secondary effects of TEA on autonomic function 30 minutes after the testing meal; pancreatic polypeptide (PP, indication of vagal activity) will be assessed using ELISA autonomic function. 42 days
Secondary effects of TEA on autonomic function 30 minutes after the testing meal; pancreatic polypeptide (PP, indication of vagal activity) will be assessed using ELISA autonomic function. 70 days
Secondary effects of TEA on autonomic function 60 minutes after the testing meal; pancreatic polypeptide (PP, indication of vagal activity) will be assessed using ELISA autonomic function. 1 day
Secondary effects of TEA on autonomic function 60 minutes after the testing meal; pancreatic polypeptide (PP, indication of vagal activity) will be assessed using ELISA autonomic function. 28 days
Secondary effects of TEA on autonomic function 60 minutes after the testing meal; pancreatic polypeptide (PP, indication of vagal activity) will be assessed using ELISA autonomic function. 42 days
Secondary effects of TEA on autonomic function 60 minutes after the testing meal; pancreatic polypeptide (PP, indication of vagal activity) will be assessed using ELISA autonomic function. 70 days
Secondary effects of TEA on GI hormones and inflammatory cytokine baseline before the study; vasoactive intestinal peptide (VIP) 1 day
Secondary effects of TEA on GI hormones and inflammatory cytokine baseline before the study; vasoactive intestinal peptide (VIP) 28 days
Secondary effects of TEA on GI hormones and inflammatory cytokine baseline before the study; vasoactive intestinal peptide (VIP) 42 days
Secondary effects of TEA on GI hormones and inflammatory cytokine baseline before the study; vasoactive intestinal peptide (VIP) 70 days
Secondary effects of TEA on GI hormones and inflammatory cytokine 30 minutes after the testing meal; vasoactive intestinal peptide (VIP) 1 day
Secondary effects of TEA on GI hormones and inflammatory cytokine 30 minutes after the testing meal; vasoactive intestinal peptide (VIP) 28 days
Secondary effects of TEA on GI hormones and inflammatory cytokine 30 minutes after the testing meal; vasoactive intestinal peptide (VIP) 42 days
Secondary effects of TEA on GI hormones and inflammatory cytokine 30 minutes after the testing meal; vasoactive intestinal peptide (VIP) 70 days
Secondary effects of TEA on GI hormones and inflammatory cytokine 60 minutes after the testing meal; vasoactive intestinal peptide (VIP) 1 day
Secondary effects of TEA on GI hormones and inflammatory cytokine 60 minutes after the testing meal; vasoactive intestinal peptide (VIP) 28 days
Secondary effects of TEA on GI hormones and inflammatory cytokine 60 minutes after the testing meal; vasoactive intestinal peptide (VIP) 42 days
Secondary effects of TEA on GI hormones and inflammatory cytokine 60 minutes after the testing meal; vasoactive intestinal peptide (VIP) 70 days
Secondary effects of TEA on GI hormones and inflammatory cytokine baseline before the study; interleukin-10 (IL-10) day 1
Secondary effects of TEA on GI hormones and inflammatory cytokine baseline before the study; interleukin-10 (IL-10) 28 days
Secondary effects of TEA on GI hormones and inflammatory cytokine baseline before the study; interleukin-10 (IL-10) 42 days
Secondary effects of TEA on GI hormones and inflammatory cytokine baseline before the study; interleukin-10 (IL-10) 70 days
Secondary effects of TEA on GI hormones and inflammatory cytokine 30 minutes after the testing meal; interleukin-10 (IL-10) 1 day
Secondary effects of TEA on GI hormones and inflammatory cytokine 30 minutes after the testing meal; interleukin-10 (IL-10) 28 days
Secondary effects of TEA on GI hormones and inflammatory cytokine 30 minutes after the testing meal; interleukin-10 (IL-10) 42 days
Secondary effects of TEA on GI hormones and inflammatory cytokine 30 minutes after the testing meal; interleukin-10 (IL-10) 70 days
Secondary effects of TEA on GI hormones and inflammatory cytokine 60 minutes after the testing meal; interleukin-10 (IL-10) 1 day
Secondary effects of TEA on GI hormones and inflammatory cytokine 60 minutes after the testing meal; interleukin-10 (IL-10) 28 days
Secondary effects of TEA on GI hormones and inflammatory cytokine 60 minutes after the testing meal; interleukin-10 (IL-10) 42 days
Secondary effects of TEA on GI hormones and inflammatory cytokine 60 minutes after the testing meal; interleukin-10 (IL-10) 70 days
Secondary effects of TEA on GI hormones and inflammatory cytokine baseline before the study; interferon a(IFNa) 1 day
Secondary effects of TEA on GI hormones and inflammatory cytokine baseline before the study; interferon a(IFNa) 28 days
Secondary effects of TEA on GI hormones and inflammatory cytokine baseline before the study; interferon a(IFNa) 42 days
Secondary effects of TEA on GI hormones and inflammatory cytokine baseline before the study; interferon a(IFNa) 70 days
Secondary effects of TEA on GI hormones and inflammatory cytokine 30 minutes after the testing meal; interferon a(IFNa) 1 day
Secondary effects of TEA on GI hormones and inflammatory cytokine 30 minutes after the testing meal; interferon a(IFNa) 28 days
Secondary effects of TEA on GI hormones and inflammatory cytokine 30 minutes after the testing meal; interferon a(IFNa) 42 days
Secondary effects of TEA on GI hormones and inflammatory cytokine 30 minutes after the testing meal; interferon a(IFNa) 70 days
Secondary effects of TEA on GI hormones and inflammatory cytokine 60 minutes after the testing meal; interferon a(IFNa) 1 day
Secondary effects of TEA on GI hormones and inflammatory cytokine 60 minutes after the testing meal; interferon a(IFNa) 28 days
Secondary effects of TEA on GI hormones and inflammatory cytokine 60 minutes after the testing meal; interferon a(IFNa) 42 days
Secondary effects of TEA on GI hormones and inflammatory cytokine 60 minutes after the testing meal; interferon a(IFNa) 70 days
Secondary effects of TEA on GI hormones and inflammatory cytokine baseline before the study; interleukin-1 beta (IL-1ß) 1 day
Secondary effects of TEA on GI hormones and inflammatory cytokine baseline before the study; interleukin-1 beta (IL-1ß) 28 days
Secondary effects of TEA on GI hormones and inflammatory cytokine baseline before the study; interleukin-1 beta (IL-1ß) 42 days
Secondary effects of TEA on GI hormones and inflammatory cytokine baseline before the study; interleukin-1 beta (IL-1ß) 70 days
Secondary effects of TEA on GI hormones and inflammatory cytokine 30 minutes after the testing meal; interleukin-1 beta (IL-1ß) 1 day
Secondary effects of TEA on GI hormones and inflammatory cytokine 30 minutes after the testing meal; interleukin-1 beta (IL-1ß) 28 days
Secondary effects of TEA on GI hormones and inflammatory cytokine 30 minutes after the testing meal; interleukin-1 beta (IL-1ß) 42 days
Secondary effects of TEA on GI hormones and inflammatory cytokine 30 minutes after the testing meal; interleukin-1 beta (IL-1ß) 70 days
Secondary effects of TEA on GI hormones and inflammatory cytokine 60 minutes after the testing meal; interleukin-1 beta (IL-1ß) 1 day
Secondary effects of TEA on GI hormones and inflammatory cytokine 60 minutes after the testing meal; interleukin-1 beta (IL-1ß) 28 days
Secondary effects of TEA on GI hormones and inflammatory cytokine 60 minutes after the testing meal; interleukin-1 beta (IL-1ß) 42 days
Secondary effects of TEA on GI hormones and inflammatory cytokine 60 minutes after the testing meal; interleukin-1 beta (IL-1ß) 70 days
Secondary effects of TEA on GI hormones and inflammatory cytokine baseline before the study; interleukin-6 (IL-6) 1 day
Secondary effects of TEA on GI hormones and inflammatory cytokine baseline before the study; interleukin-6 (IL-6) 28 days
Secondary effects of TEA on GI hormones and inflammatory cytokine baseline before the study; interleukin-6 (IL-6) 42 days
Secondary effects of TEA on GI hormones and inflammatory cytokine baseline before the study; interleukin-6 (IL-6) 70 days
Secondary effects of TEA on GI hormones and inflammatory cytokine 30 minutes after the testing meal; interleukin-6 (IL-6) 1 day
Secondary effects of TEA on GI hormones and inflammatory cytokine 30 minutes after the testing meal; interleukin-6 (IL-6) 28 days
Secondary effects of TEA on GI hormones and inflammatory cytokine 30 minutes after the testing meal; interleukin-6 (IL-6) 42 days
Secondary effects of TEA on GI hormones and inflammatory cytokine 30 minutes after the testing meal; interleukin-6 (IL-6) 70 days
Secondary effects of TEA on GI hormones and inflammatory cytokine 60 minutes after the testing meal; interleukin-6 (IL-6) 1 day
Secondary effects of TEA on GI hormones and inflammatory cytokine 60 minutes after the testing meal; interleukin-6 (IL-6) 28 days
Secondary effects of TEA on GI hormones and inflammatory cytokine 60 minutes after the testing meal; interleukin-6 (IL-6) 42 days
Secondary effects of TEA on GI hormones and inflammatory cytokine 60 minutes after the testing meal; interleukin-6 (IL-6) 70 days
Secondary effects of TEA on GI hormones and inflammatory cytokine baseline before the study; tumor necrosis factor alpha(TNFa) day 1
Secondary effects of TEA on GI hormones and inflammatory cytokine baseline before the study; tumor necrosis factor alpha(TNFa) 28 days
Secondary effects of TEA on GI hormones and inflammatory cytokine baseline before the study; tumor necrosis factor alpha(TNFa) 42 days
Secondary effects of TEA on GI hormones and inflammatory cytokine baseline before the study; tumor necrosis factor alpha(TNFa) 70 days
Secondary effects of TEA on GI hormones and inflammatory cytokine 30 minutes after the testing meal; tumor necrosis factor alpha(TNFa) 1 day
Secondary effects of TEA on GI hormones and inflammatory cytokine 30 minutes after the testing meal; tumor necrosis factor alpha(TNFa) 28 days
Secondary effects of TEA on GI hormones and inflammatory cytokine 30 minutes after the testing meal; tumor necrosis factor alpha(TNFa) 42 days
Secondary effects of TEA on GI hormones and inflammatory cytokine 30 minutes after the testing meal; tumor necrosis factor alpha(TNFa) 70 days
Secondary effects of TEA on GI hormones and inflammatory cytokine 60 minutes after the testing meal; tumor necrosis factor alpha(TNFa) 1 day
Secondary effects of TEA on GI hormones and inflammatory cytokine 60 minutes after the testing meal; tumor necrosis factor alpha(TNFa) 28 days
Secondary effects of TEA on GI hormones and inflammatory cytokine 60 minutes after the testing meal; tumor necrosis factor alpha(TNFa) 42 days
Secondary effects of TEA on GI hormones and inflammatory cytokine 60 minutes after the testing meal; tumor necrosis factor alpha(TNFa) 70 days
See also
  Status Clinical Trial Phase
Completed NCT03941288 - Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia Phase 2
Terminated NCT03285308 - A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01 Phase 3
Completed NCT00733551 - Evaluation of the Safety, Tolerability and Pharmacokinetics of Repeat Oral Doses of GSK962040 Administered to Healthy Adult Subjects. Phase 1
Completed NCT01650714 - Endoscopic Full Thickness Biopsy, Gastric Wall. N/A
Completed NCT01452815 - Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis Phase 2
Completed NCT01039974 - GSK962040 Drug-drug Interaction Study With Ketoconazole Phase 1
Terminated NCT04844190 - Use of EndoFLIP and Manometry Prior to G-POEM N/A
Enrolling by invitation NCT06215547 - Medtronic Enterra II Neurostimulator N/A
Completed NCT04026997 - A Phase 2 Study of CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis Phase 2
Completed NCT00562848 - A Study to Evaluate Safety, Side Effects, Muscle Activity and Speed of Gastric Emptying of GSK962040 Phase 1
Enrolling by invitation NCT04207996 - Vagus Nerve Response in Gastroparesis Patients
Completed NCT04607304 - ABCA2 GIRMS Analytical Validation Clinical Performance Study N/A
Recruiting NCT06068114 - Gastric Pathophysiology in Diabetes
Completed NCT03259841 - Ultrasound Assessment of Gastric Contents in Fasted Patient Undergoing Cholecystectomy
Active, not recruiting NCT04300127 - Pioglitazone for Idiopathic Gastroparesis Early Phase 1
Recruiting NCT01696734 - Domperidone in Treating Patients With Gastrointestinal Disorders Phase 3
Terminated NCT04635306 - 13C-Spirulina Nitrogen Content GEBT Study N/A
Withdrawn NCT02420925 - Effect of Celiac Plexus Block on Gastric Emptying and Symptoms Caused by Gastroparesis N/A
Recruiting NCT00777439 - Domperidone for Refractory Gastrointestinal Disorders N/A
Terminated NCT00760461 - Domperidone in Refractory Gastroparesis Phase 2